EUVIMEDEUVIMED entdecken
Crossref

Prognostic Study of NT ‐ proBNP in Heart Failure Patients With Left Ventricular Assist Device Implantation

Yuxin Zhang, Entao Lian, Xinyi Wang, Ze Hou, Rui Jing iD, Kegang Jia, Zhigang Liu

Artificial Organs · 2026-06 · 50 (6) · 899-908

DOI: 10.1111/aor.70113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Organs, online erschienen am 18.03.2026. Verfasst von Yuxin Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical School of Cardiovascular Disease, Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Natriuretic Peptide, Brain, Heart-Assist Devices, Heart Failure, Peptide Fragments. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Tianjin Key Medical Discipline Construction Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the dynamic changes in N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) and cardiac Troponin I (cTnI) after left ventricular assist device (LVAD) implantation in patients with end‐stage heart failure (ESHF), and to evaluate their prognostic value in predicting major adverse cardiac events (MACE), as well as to analyze the correlation between NT‐proBNP and pump speed.

Methods

A total of 78 ESHF patients implanted with the HeartCon LVAD between September 2020 and March 2025 were enrolled. Levels of NT‐proBNP and cTnI were measured preoperatively and on postoperative days (POD) 1, 7, 30, 60, and 90. Patients were followed for MACE (death or rehospitalization for right heart failure) within 6 months. Receiver operating characteristic (ROC) analysis, Cox regression, and Kaplan–Meier (KM) survival curves were used to evaluate prognostic indicators. Spearman analysis was applied to assess the correlation between NT‐proBNP and pump speed.

Results

NT‐proBNP showed a significant reduction from a preoperative level of 4336.51 pg/mL to 2916.03 pg/mL on postoperative Day 1 ( p = 0.01) and continued to decline, reaching 869.50 pg/mL by Day 90, although it remained above the upper reference limit. Total bilirubin (TBIL) increased markedly on Day 1 (from 16.60 to 32.70 μmol/L, p < 0.001) but returned to normal by Day 30 (11.30 μmol/L). cTnI peaked on Day 1 (from 0.58 to 18.93 ng/mL, p < 0.001), decreased significantly by Day 7 (to 2.24 ng/mL, p < 0.001), and normalized by Day 30 (0.15 ng/mL). ROC analysis showed that NT‐proBNP on POD7 predicted MACE with an AUC of 0.749 ( p = 0.004). Cox regression indicated that patients with NT‐proBNP ≥ 2983 pg/mL on POD7 had a 6.2‐fold higher risk of MACE (HR = 6.163, p = 0.001). Spearman analysis revealed a positive correlation between NT‐proBNP and pump speed in the MACE(+) group ( r = 0.314, p = 0.011).

Conclusion

LVAD effectively unloaded the left ventricle, leading to a significant reduction in NT‐proBNP. NT‐proBNP on POD7 served as an independent predictor of MACE. Moreover, pump speed positively correlated with NT‐proBNP levels. Our findings provided a clinical evidence base supporting the application of precision medicine in the management of ESHF patients with LVAD implantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Natriuretic Peptide, BrainHeart-Assist DevicesHeart FailurePeptide FragmentsHumansFemaleMalePrognosisTroponin IMiddle AgedBiomarkersAgedAdult

Stichwörter der Autor:innen

N‐terminal pro‐B‐type natriuretic peptideleft ventricular assist devicemajor adverse cardiac eventspump speed

Substanzen

Natriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)Peptide FragmentsTroponin IBiomarkers

Autor:innen und Institutionen

  • Clinical School of Cardiovascular Disease, Tianjin Medical University, Tianjin, China.
  • Graduate School of Chengde Medical University, Chengde, China.
  • Department of Clinical Laboratory, The Institute of Cardiovascular Diseases & TEDA International Cardiovascular Hospital, Tianjin University, Tianjin, China.
  • Department of Heart Failure, The Institute of Cardiovascular Diseases & TEDA International Cardiovascular Hospital, Tianjin University, Tianjin, China.
  • Department of Cardiovascular Surgery, The Institute of Cardiovascular Diseases & TEDA International Cardiovascular Hospital, Tianjin University, Tianjin, China.

ORCID-Profile: Rui Jing

Förderung

  • Tianjin Key Medical Discipline Construction Project

Zitieren

APA

Zhang, Y., Lian, E., Wang, X., Hou, Z., Jing, R., Jia, K., & Liu, Z. (2026). Prognostic Study of NT ‐ proBNP in Heart Failure Patients With Left Ventricular Assist Device Implantation. Artificial Organs, 50(6), 899-908. https://doi.org/10.1111/aor.70113

Vancouver

Zhang Y, Lian E, Wang X, Hou Z, Jing R, Jia K, et al. Prognostic Study of NT ‐ proBNP in Heart Failure Patients With Left Ventricular Assist Device Implantation. Artificial Organs. 2026;50(6):899-908. doi:10.1111/aor.70113

BibTeX
@article{Zhang2026,
  author = {Zhang, Yuxin and Lian, Entao and Wang, Xinyi and Hou, Ze and Jing, Rui and Jia, Kegang and Liu, Zhigang},
  title = {Prognostic Study of NT ‐ proBNP in Heart Failure Patients With Left Ventricular Assist Device Implantation},
  journal = {Artificial Organs},
  year = {2026},
  volume = {50},
  number = {6},
  pages = {899--908},
  doi = {10.1111/aor.70113}
}
Kostenlos starten →